急性早幼粒细胞白血病合并弥散性血管内凝血183例

目的探讨急性早幼粒细胞白血病（APL）合并弥散性血管内凝血（DIC）的治疗效果。方法对全反式维甲酸（ATRA）＋三氧化二砷（As2O3）或两者交替、单用ATRA、造血干细胞移植（HSCT）3种治疗方案的疗效进行比较。结果采用ATRA＋As2O3或者两者交替组获得CR中位时间分别为34d、35．5d，单用ATRA获得CR中位时间为62d，差异有统计学意义（P〈0．05）。ATRA＋As2O3组或两者交替组，3年无病生存率分别为78％和80％，与单用ATRA组比较，差异有统计学意义（P〈0．05），DIC纠正时间为16～18d，三种治疗方案差异无统计学意义。15例行HSCT者，仅2例复发，其余13例中位无病生存时间（DFS）为13．5年，该13例PCR检测PML-RAα仅融合基因阴性。结论应用ATRA＋As2O3或两者交替加成分血、抗纤溶纠正DIC及其化疗治疗APL获得CR时间明显缩短，而且3年无病生存率相对较高。缓解后6个月讲行HSCT者．DFS可讲一步延长。

The analysis of 183 patients with acute promyelocytic leukemia accompanied by disseminated intravascular coagulation

Objective To analyse the outcome of different regimens for the treatment to patients with aeute promyelocytic leukemia(APL)accompanied by disseminated intravagcular coagulation(DIC).Methods The outcome of different chemotherapy regimens was compared. Results The median time achieving complete remission by all-trans retinoic acid(ATRA)combined with arsenic trioxide(As2O3)or alternative of ATRA and As2O3 were 34 days and 35.5 days,respectively.The median time of CR for the patients treated with ATRA only was 62 days.There is a statistical difference where three-year disease-free survival rates of the patients given by ATRA and As2O3 or alternative of them were 78 percent and 80 percent,respectively.Compared with the patients administered with ATRA only.there is significant difference(P＜0.05).The time of improving DIC was about 16 days to 18 days.There was no significant difference among this three chemotherapy regimens.Among 15 patients with autologous henmtopeietic stem cell transplantation,the disease-free survival time of 13 cases.who have no PML-RARα gene deteced by PCR was 13.5 years except 2 cases with relapse.Conclusion The time achieving complete remission of APL was reduced dramaticaly by administering all-trans retinoic acid(ATRA)combined with arsenic trioxide(As2O3)or alternative treatment of them and principles of blood transfusion and anti-fibmolysis to improve DIC,this regimen showed a relatively higher three-year disease-free survival (DFS) rate.These cases who received hematopeietic stem cell transplantation after six mortths of remission,DFS time wag further prolonged.